Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients

Recruiting

• Conditions: COVID-19 Convalescent Plasma Treatment

• Registration Number: NCT05905380
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-02
• Status Verified: 2023-06
• Study First Submitted: 2023-06-14
• Study First Submitted QC: 2023-06-14
• Study First Posted: 2023-06-15
• Last Update Submitted: 2023-06-15
• Last Update Posted: 2023-06-18
• Primary Completion: 2024-01-31
• Study Completion: 2024-01-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective analysis of the tolerance of Covid-19 convalescent plasma and monoclonal antibodies in the treatment of SARS-Cov2 infections in immunocompromised patients	Files analysed retrospectively from February 25, 2020 to January 15, 2023 will be examined	This is a retrospective study on patient data from medical records from February 25, 2020 to January 15, 2023

Trial Locations

Locations (1)

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France